% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Jin:276063,
      author       = {F. Jin$^*$ and Z. Yang and J. Shao and J. Tao$^*$ and C.
                      Reißfelder and S. Loges$^*$ and L. Zhu$^*$ and S.
                      Schölch$^*$},
      title        = {{ARID}1{A} mutations in lung cancer: biology, prognostic
                      role, and therapeutic implications.},
      journal      = {Trends in molecular medicine},
      volume       = {29},
      number       = {8},
      issn         = {1471-4914},
      address      = {Amsterdam [u.a.]},
      publisher    = {Elsevier Science},
      reportid     = {DKFZ-2023-00969},
      pages        = {646-658},
      year         = {2023},
      note         = {#EA:A430#LA:A430# / 2023 Aug;29(8):646-658},
      abstract     = {Mutations in the AT-interacting domain-rich protein 1A
                      (ARID1A) gene, a critical component of the switch/sucrose
                      nonfermentable (SWI/SNF) complex, are frequently found in
                      most human cancers. Approximately $5-10\%$ of lung cancers
                      carry ARID1A mutations. ARID1A loss in lung cancer
                      correlates with clinicopathological features and poor
                      prognosis. Co-mutation of ARID1A and epidermal growth factor
                      receptor (EGFR) results in the limited efficacy of EGFR
                      tyrosine kinase inhibitors (EGFR-TKIs) but increases the
                      clinical benefit of immune checkpoint inhibitors (ICIs).
                      ARID1A gene mutation plays a role in cell cycle regulation,
                      metabolic reprogramming, and epithelial-mesenchymal
                      transition. We present the first comprehensive review of the
                      relationship between ARID1A gene mutations and lung cancer
                      and discuss the potential of ARID1A as a new molecular
                      target.},
      subtyp        = {Review Article},
      keywords     = {ARID1A (Other) / SWI/SNF complex (Other) / cell cycle
                      regulation (Other) / epithelial–mesenchymal transition
                      (Other) / lung cancer (Other) / metabolic reprogramming
                      (Other)},
      cin          = {A430 / A420},
      ddc          = {610},
      cid          = {I:(DE-He78)A430-20160331 / I:(DE-He78)A420-20160331},
      pnm          = {311 - Zellbiologie und Tumorbiologie (POF4-311)},
      pid          = {G:(DE-HGF)POF4-311},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:37179132},
      doi          = {10.1016/j.molmed.2023.04.005},
      url          = {https://inrepo02.dkfz.de/record/276063},
}